|
|
Volumn 69, Issue 1, 2016, Pages 4-6
|
|
Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AXITINIB;
CABOZANTINIB;
EVEROLIMUS;
NIVOLUMAB;
SORAFENIB;
VASCULOTROPIN;
ANILIDE;
ANTINEOPLASTIC AGENT;
MONOCLONAL ANTIBODY;
PYRIDINE DERIVATIVE;
VASCULOTROPIN A;
CANCER SURVIVAL;
CLINICAL ASSESSMENT;
CLINICAL EVALUATION;
DRUG TREATMENT FAILURE;
HEALTH CARE QUALITY;
HUMAN;
IMMUNE RESPONSE;
KIDNEY CARCINOMA;
MOLECULARLY TARGETED THERAPY;
OUTCOME ASSESSMENT;
OVERALL SURVIVAL;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
PROTEIN TARGETING;
REVIEW;
TREATMENT DURATION;
TREATMENT INDICATION;
ANTAGONISTS AND INHIBITORS;
CARCINOMA, RENAL CELL;
KIDNEY NEOPLASMS;
RETREATMENT;
TREATMENT FAILURE;
ANILIDES;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
CARCINOMA, RENAL CELL;
EVEROLIMUS;
HUMANS;
KIDNEY NEOPLASMS;
PRACTICE GUIDELINES AS TOPIC;
PYRIDINES;
RETREATMENT;
TREATMENT FAILURE;
VASCULAR ENDOTHELIAL GROWTH FACTOR A;
|
|
EID: 84955488717
PISSN: 03022838
EISSN: 18737560
Source Type: Journal
DOI: 10.1016/j.eururo.2015.10.017 Document Type: Editorial |
|
Times cited : (95)
|
|
References (6)
|
